Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function. This tool will be launched as ...

This is Part 6 of Embedded Bias, a series revealing how race-based clinical algorithms pervade medicine and why it's so difficult to change them. NEW YORK — One Brooklyn Health, a safety net hospital ...

For patients with the triad of chronic kidney disease, type 2 diabetes, and hypertension, the use of an electronic health record-based algorithm and intervention does not result in reduced ...

Roche Holdings AG received CE-mark for the Kidney Klinrisk algorithm, an AI-based tool developed in collaboration with Klinrisk Inc. to stratify risk and assess the progressive decline in kidney ...

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...

For years, it was harder for Black patients to secure a coveted spot on the national kidney transplant waitlist because a clinical algorithm was making Black patients appear healthier than they were.

Panelists discuss how recent data from the KEYNOTE-564 trial has changed their approaches to treating patients with renal cell carcinoma by implementing adjuvant pembrolizumab therapy for high-risk ...